Compare Pfizer with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs FRESENIUS KABI ONCO. - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER FRESENIUS KABI ONCO. PFIZER/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 32.6 22.1 147.5% View Chart
P/BV x 5.5 3.1 175.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PFIZER
Mar-18
FRESENIUS KABI ONCO.
Mar-13
PFIZER/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs2,365176 1,343.8%   
Low Rs1,62579 2,070.1%   
Sales per share (Unadj.) Rs430.337.7 1,141.7%  
Earnings per share (Unadj.) Rs78.75.1 1,545.3%  
Cash flow per share (Unadj.) Rs93.26.7 1,386.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.542.5 1,378.5%  
Shares outstanding (eoy) m45.75158.23 28.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.63.4 137.3%   
Avg P/E ratio x25.325.0 101.5%  
P/CF ratio (eoy) x21.418.9 113.1%  
Price / Book Value ratio x3.43.0 113.7%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,27120,135 453.3%   
No. of employees `0002.61.2 228.3%   
Total wages/salary Rs m3,143703 446.9%   
Avg. sales/employee Rs Th7,484.85,176.2 144.6%   
Avg. wages/employee Rs Th1,195.0610.4 195.8%   
Avg. net profit/employee Rs Th1,369.1699.6 195.7%   
INCOME DATA
Net Sales Rs m19,6855,963 330.1%  
Other income Rs m1,14318 6,349.4%   
Total revenues Rs m20,8285,981 348.2%   
Gross profit Rs m5,0031,430 349.8%  
Depreciation Rs m663258 256.9%   
Interest Rs m4-26 -16.2%   
Profit before tax Rs m5,4791,216 450.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,878342 548.9%   
Profit after tax Rs m3,601806 446.8%  
Gross profit margin %25.424.0 106.0%  
Effective tax rate %34.328.1 121.8%   
Net profit margin %18.313.5 135.3%  
BALANCE SHEET DATA
Current assets Rs m24,1675,102 473.7%   
Current liabilities Rs m9,5442,385 400.1%   
Net working cap to sales %74.345.6 163.1%  
Current ratio x2.52.1 118.4%  
Inventory Days Days55150 36.7%  
Debtors Days Days29113 25.3%  
Net fixed assets Rs m9,5145,148 184.8%   
Share capital Rs m458158 289.2%   
"Free" reserves Rs m26,3756,556 402.3%   
Net worth Rs m26,8326,732 398.6%   
Long term debt Rs m25952 2.6%   
Total assets Rs m36,90010,388 355.2%  
Interest coverage x1,305.5-45.8 -2,852.0%   
Debt to equity ratio x00.1 0.7%  
Sales to assets ratio x0.50.6 92.9%   
Return on assets %9.87.5 130.1%  
Return on equity %13.412.0 112.1%  
Return on capital %20.414.6 139.8%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m225,298 0.4%   
Fx outflow Rs m1,4891,772 84.0%   
Net fx Rs m-1,4663,525 -41.6%   
CASH FLOW
From Operations Rs m3,3181,274 260.4%  
From Investments Rs m-2,383-1,204 197.9%  
From Financial Activity Rs m-1,104-196 562.7%  
Net Cashflow Rs m-169-126 133.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 81.0 78.9%  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 4.9 9.6 51.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 9.1 260.4%  
Shareholders   85,207 42,599 200.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Energy & Realty Stocks Lead(09:30 am)

Asian share markets are higher today as Britain and the EU made headway on a Brexit deal ahead of a leaders' summit.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 16, 2019 10:07 AM

TRACK PFIZER

PFIZER - FRESENIUS KABI ONCO. COMPARISON

COMPARE PFIZER WITH

MARKET STATS